Heart disease is the leading cause of death in the United States. To develop targeted therapeutic approaches for heart and skeletal muscle diseases it is critical to first understand the molecular mechanisms regulating contractile activation and relaxation. We study how different isoforms of myofilament proteins manifest in the different functional properties of the two striated muscle types and how alterations in these proteins lead to changes in function. Progress from this award has clearly demonstrated mechanistic differences in the cooperative activation of cardiac vs. skeletal muscle that suggest different strategies may be needed to improving contraction in impaired tissue. These differences may allow for greater cellular level of controlling force in cardiac muscle, which is required to match stroke volume with venous return on a beat-to-beat basis, i.e. the Frank-Starling Law of the Heart. Additionally, two approaches developed in this award have led to gene delivery-based methods of improving cardiomyocyte function, which is the subject of a new R21 award. In the current proposal we continue to use parallel experiments with cardiac and skeletal systems to study troponin subunit interactions and their role in setting the Ca2+sensitivity of myofilament contraction, and will look for additional mutants that improve cardiac and skeletal muscle function. Our experiments use a variety of recombinant protein mutants, sophisticated solution biochemical techniques and functional analysis at the level of individual myofilaments, myofibrils cells and tissue. In addition to activation and SL- dependence of contraction, we will now study how troponin subunit interaction properties affect relaxation. This is an understudied but quite important question, in as much as 50% of heart failure may be attributable to diastolic dysfunction. Another new area for the proposal is to study how tropomyosin and myosin isoform composition may influence to coordinated activity of myofilament proteins in determining activation and relaxation kinetics. Finally we will develop a novel 3D-myofilament half- sarcomere model that is 1) spatially explicit and contains the stochastic kinetics of cycling crossbridges and thin filament dynamics and 2) incorporates radial forces associated with actomyosin interaction for more realistic simulation of the SL-dependence of force and understanding of the mechanic-kinetic aspects of relaxation.

Public Health Relevance

A myriad of cardiac and skeletal muscle diseases involve compromised contractility. Our work focuses on understanding the detailed mechanisms of contractile activation and regulation in these two muscle types, with the long-term goal of finding targeted approaches to improve contractile function. The work uses a combination of recombinant DNA technology, sophisticated protein solution characterization techniques, and mechanical measurements of isolated myofilament, myofibrils and muscle cells to study these mechanisms and develop approaches that improve contractile performance.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CVS-D (02))
Program Officer
Liang, Isabella Y
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Biomedical Engineering
Schools of Engineering
United States
Zip Code
Teichman, Sam L; Thomson, Kassandra S; Regnier, Michael (2017) Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction. Handb Exp Pharmacol 243:447-464
Racca, Alice W; Klaiman, Jordan M; Pioner, J Manuel et al. (2016) Contractile properties of developing human fetal cardiac muscle. J Physiol 594:437-52
Thomson, Kassandra S; Odom, Guy L; Murry, Charles E et al. (2016) Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy. JACC Basic Transl Sci 1:666-679
Feest, Erik R; Steven Korte, F; Tu, An-Yue et al. (2014) Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts. J Mol Cell Cardiol 72:219-27
Thomson, Kassandra S; Dupras, Sarah K; Murry, Charles E et al. (2014) Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses. Angiogenesis 17:195-205
Rao, Vijay; Cheng, Yuanhua; Lindert, Steffen et al. (2014) PKA phosphorylation of cardiac troponin I modulates activation and relaxation kinetics of ventricular myofibrils. Biophys J 107:1196-1204
Cheng, Yuanhua; Lindert, Steffen; Kekenes-Huskey, Peter et al. (2014) Computational studies of the effect of the S23D/S24D troponin I mutation on cardiac troponin structural dynamics. Biophys J 107:1675-85
Racca, Alice W; Beck, Anita E; Rao, Vijay S et al. (2013) Contractility and kinetics of human fetal and human adult skeletal muscle. J Physiol 591:3049-61
Wang, Dan; McCully, Michelle E; Luo, Zhaoxiong et al. (2013) Structural and functional consequences of cardiac troponin C L57Q and I61Q Ca(2+)-desensitizing variants. Arch Biochem Biophys 535:68-75
Rao, Vijay S; Korte, F Steven; Razumova, Maria V et al. (2013) N-terminal phosphorylation of cardiac troponin-I reduces length-dependent calcium sensitivity of contraction in cardiac muscle. J Physiol 591:475-90

Showing the most recent 10 out of 36 publications